Pharmaxis completes trial recruitment

Company News

by Jessica Ellerm

Pharmaxis (ASX:PXS) has announced it has completed recruitment of an international clinical trial evaluating its Bronchitol drug.
Subject to a positive trial outcome, the company will seek approval from the US FDA to distribute the drug in the US.
Bronchitol is used to treat patients suffering from Cystic Fibrosis and is currently approved for use in Australia, the EU and Israel.
Pharmaxis has partnered with global pharmaceutical provider Chiesi to fund the trials and to sell and distribute the product.
Pharmaxis reported a net loss of $11.18 million at 31 December 2015.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.